See Supplemental Patient Information
- Exercise caution in patients with debilitating medical conditions such as cardiovascular disease, severe pulmonary disease, or diabetes mellitus with ketoacidosis as therapy may be associated with fever and other flu-like symptoms
- Discontinue therapy and initiate appropriate medical therapy if acute, serious hypersensitivity reactions occur
- Therapy may carry a risk of transmitting infectious agents such as viruses and Creutzfeldt-Jakob disease (CJD) agent because this product is derived from human blood
- Interferon products are not interchangeable as the manufacturing process, strength, and type of interferon may vary for different interferon formulations
Cautions: Use cautiously in
- Coagulation disorders
- Severe myelosuppression
- Seizure disorders
Supplemental Patient Information
- Inform patients of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis; advise them to contact their physicians if these symptoms occur
- Caution patients not to interchange brands of interferon without consulting their physicians, as it may require change is dosage
Pregnancy Category:C
Breastfeeding: It is unknown whether interferon alfa-n3 is excreted in human milk. As many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or treatment, analyzing the importance of the drug to the mother and the potential risks to the infant.
18 yrs of age
